Voximetry Exhibits at SNMICON 2022 New Delhi, India
Voximetry is very pleased to participate in the 54th Annual Conference of the Society of Nuclear Medicine (India), SNMICON 2022, from December 8th -12th. We invite you to visit us during the exhibition at the booth of BJ. Madan & Co. and learn how Torch®, the accuracy leader and only full Monte Carlo GPU-accelerated voxel-based […]
Voximetry Receives FDA Clearance For Torch
MADISION, WI – Voximetry is very pleased to announce FDA 510(k) market clearance for Torch® Dose Assessment for Radiopharmaceutical Therapy (RPT), the first commercial full Monte Carlo GPU-accelerated voxel-based dosimetry solution. Torch can provide estimates of absorbed radiation dose following internal administration of approved radiopharmaceuticals, Torch can provide estimates of absorbed radiation dose in seconds. […]
Voximetry welcomes Dr. Richard Wahl as Chair of Scientific and Clinical Advisory Board
Voximetry is pleased to welcome Dr. Richard Wahl as Chair of the Scientific & Clinical Advisory Board for the company. Dr. Wahl was among the first to precisely target internal radiation therapy to cancers and has a successful track record of innovation from pre-clinical research to the clinic. His significant translational success includes 20 patents, […]
Voximetry signs new collaboration with Gemelli University Hospital IRCCS
Voximetry is proud to announce a product evaluation and research collaboration agreement for Torch® voxel-based Dose Assessment with Fondazione Policlinico Universitario A. Gemelli IRCCS. The collaboration intends to utilize Voximetry’s Torch® software* to research how a radiotherapeutic agent distributes in a specific patient and then report or predict the biologic effect on each tumor or […]
Voximetry Wins
“2022 Pressure Chamber”
Investor Pitch Competition
The Madison Wisconsin Chamber of Commerce “Pressure Chamber” event returned for its ninth year as emerging companies again competed for the coveted “golden suitcase,” as well as a reserved spot in the Chamber’s exclusive Greater Madison startup meetings with top Silicon Valley investment firms this fall. Over 300 companies competed to pitch in front of […]
Voximetry selected as finalist for the 2022 Wisconsin Innovation Awards
Voximetry is proud to announce we have been selected as a finalist from more than 300 businesses, products and services for the 2022 Wisconsin Innovation Awards. We are extremely grateful for the opportunity to share our exciting work on personalized RPT treatment planning making a difference for cancer patients everywhere. For more information, click here. […]
Voximetry will be at Theranostics World Congress, Wiesbaden Germany
Voximetry Inc., is pleased to support and participate in the 6th Theranostics World Congress in Wiesbaden Germany from June 24-26. We invite you to visit with us at the Voximetry booth SW02 and learn more about the latest news on advanced dosimetry guidance and how you can implement personalized RPT in your clinic. *510(k) […]
Voximetry Awarded NIH SBIR Supplemental Grant
MADISON, Wis.–Voximetry Inc., a Healthtech software company with unique technology for personalized Radiopharmaceutical Therapy (RPT) has been awarded a substantial grant from the U.S. National Institutes of Health (NIH)’s National Cancer Institute (NCI) to further advance development of its proprietary software for RPT dose assessment and treatment planning. According to Voximetry CEO, Dr. Sue Wallace, […]
Voximetry to Present at SNMMI Annual Meeting
Voximetry is looking forward to a busy week at the SNMMI in Vancouver! Dr. Chuck Stearns, Sr. Advanced Development Engineer will be presenting during the Saturday Categorical Seminar on “Key Factors in Quantitative PET Reconstruction“. Additionally, Voximetry is excited to highlight a poster “Impact of SPECT Reconstruction Methods on Voxel-Level Radiopharmaceutical Dosimetry”. Please visit us […]
FDA approves Pluvicto for Prostate Cancer
Novartis is a global medicine company using innovative science and digital technologies to create transformative treatments in areas of great medical need, including late-stage prostate cancer. Today it was announced the Company had received FDA Approval for Pluvicto™, the first targeted radiopharmaceutical therapy (RPT) for treatment of progressive prostate cancer. Pluvicto (Lutetium-177 vipivotide tetraxetan, commonly […]